A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02807558

A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The purpose of this study is to determine the activity of SY-1425 in patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who are positive for a RARA super-enhancer associated biomarker.

Status: 
Recruiting
Study Date: 
Mon, 08/01/2016 to Fri, 03/01/2019
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: SY-1425 (tamibarotene)